20260629_INAF_Penyampaian Bukti Iklan_32105986_lamp6.pdf

C.   There were no additional Meeting Agenda proposals from the Company's Shareholders up to the
     deadline as stipulated in Article 23 paragraph (6) letter a of the Company's Articles of Association,
     i.e., up to 7 (seven) days prior to the date of the Meeting Invitation.
D.   The Meeting was attended by all members of the Board of Commissioners and Board of Directors,
     and Shareholders of the Company, namely:
     BOARD OF COMMISSIONERS
     Commissioner                : Mr. Dr. DIDI AGUS MINTADI
     BOARD OF DIRECTORS
     President Director          : Mr. Dr. Ir. SAHAT MANAHAN SIHOMBING, MM.M.H.
     Operational Director        : Mr. Drs. ANDI PRAZOS
     as well as Shareholders and proxy representatives of Shareholders, both attending in person and
     electronically through eASY.KSEI, who collectively hold 2,925,946,300 shares including the Series A
     Dwiwarna share, representing 94.4076721% of the total shares with valid voting rights issued by the
     Company up to the date of the Meeting, totaling 3,099,267,500 shares consisting of:
     -   1 (one) Series A Dwiwarna share; and
     -   3,099,267,499 Series B shares
     with reference to the Company's Register of Shareholders as of June 2, 2026, up to 16:00 Western
     Indonesian Time.
E.   The Meeting was chaired by the Company's Commissioner, Mr. Dr. DIDI AGUS MINTADI, based on
     the Board of Commissioners' letter dated June 19, 2026, No. S-32/DK-INAF/VI/2026.
F.   The Meeting was held with the following Agenda:
     1. Approval of the Company's Annual Report for Financial Year 2025 and Ratification of the
        Company's Financial Statements for Financial Year 2025, the Board of Commissioners' Supervisory
        Duties Report for Financial Year 2025, and Ratification of the Report on the Implementation of
        the Micro and Small Business Funding Program (PUMK) for Financial Year 2025, as well as granting
        full discharge and release of liability (volledig acquit et de charge) to the Board of Directors for
        their management of the Company and to the Board of Commissioners for their supervision of
        the Company during Financial Year 2025.
     2. Determination of Salary/Honorarium along with Facilities and Allowances for Financial Year 2026,
        as well as Performance-Based Remuneration for Financial Year 2025 for the Company's
        Management.
     3. Appointment of a Public Accountant and/or Public Accounting Firm to Audit the Company's
        Financial Statements and the Financial Statements of the Micro and Small Business Funding
        Program for Financial Year 2026.
     4. Delegation of Authority to Approve the Company's Long-Term Plan (RJPP) for 2026–2030 and the
        Company's Work Plan and Budget (RKAP) for 2027 along with its amendments, from the GMS to
        the Party designated by the GMS.
     5. Change in the Company's Management.

G.   During the Meeting, a presentation on the Company's general condition was delivered by the
     Meeting Chair, Mr. Dr. DIDI AGUS MINTADI.
     During each Meeting Agenda item, shareholders and proxy representatives—both attending in
     person and electronically—were given the opportunity to raise questions and/or express opinions.
     No shareholders or proxy representatives raised questions or expressed opinions on Agenda Items
     First, Third, Fourth, and Fifth. On the First Agenda Item, 1 (one) Shareholder submitted a response.
H.   The decision-making mechanism in the Meeting was carried out through deliberation for consensus
     (musyawarah untuk mufakat) in accordance with Article 40 with reference to Article 28 of POJK No.
     15/2020. In the event that deliberation for consensus could not be reached, decisions were made by
     vote. Voting was conducted openly, counted from valid votes cast at the Meeting and through
     eASY.KSEI.
     The Meeting has adopted resolutions as set forth in the deed entitled "Minutes of Annual General
     Meeting of Shareholders for Financial Year 2025 of PT PERUSAHAAN PERSERO INDONESIA FARMA
     Tbk, abbreviated as PT Indofarma (Persero) Tbk" dated June 25, 2026, Deed No. 59, the minutes of
     which were prepared by Notary Utiek Rochmuliati Abdurachman, SH., MLI., MKn., the substance of
     which is as follows:
On the First Agenda Item of the Meeting:
Of the total shares with valid voting rights present and/or represented both in person and electronically
at the Meeting, 8,000 shares representing 0.0002734% voted Against; 100 shares representing
0.0000034% voted Abstain; while the remainder, 2,925,938,200 shares representing 99.99972328%,
including 1 (one) Series A Dwiwarna share, voted In Favor.
In accordance with the Meeting Rules of Procedure, Shareholders who did not cast a vote (abstain) are
deemed to have cast a vote consistent with the majority vote.
Accordingly, the Meeting by majority vote through deliberation for consensus, totaling 2,925,938,300
shares representing 99.9997266% of all votes cast at the Meeting, resolved:
1. To approve the Company's Annual Report including the Board of Commissioners' Supervisory Duties
   Report for Financial Year 2025 ending December 31, 2025.
2. To ratify:
     a. The Company's Financial Statements for Financial Year 2025 ending December 31, 2025, audited
        by the Public Accounting Firm Heliantono and Partners under Report No.
        00805/2.0459/AU.1/04/0916-2/1/V/2026 dated May 12, 2026, with an unqualified opinion in
        all material respects; and
     b. The Financial Statements of the Micro and Small Business Funding Program (PUMK) for Financial
        Year 2025 ending December 31, 2025, audited by the Public Accounting Firm Heliantono and
        Partners under Report No. 00833/2.0459/AU.8/04/0916-2/1/V/2026 dated May 21, 2026, with
        an unqualified opinion in all material respects.
3. With the approval of the Company's Annual Report, including the Board of Commissioners'
   Supervisory Duties Report, and the ratification of the Company's Financial Statements and the PUMK
   Program Financial Statements, all for Financial Year 2025 ending December 31, 2025, the GMS grants
   full discharge and release of liability (volledig acquit et de charge) to all members of the Board of
   Directors for their management of the Company and to all members of the Board of Commissioners

     for their supervision of the Company during Financial Year 2025 ending December 31, 2025, provided
     that such actions do not constitute criminal acts and are reflected in the aforementioned Reports.


On the Second Agenda Item of the Meeting:
Of the total shares with valid voting rights present and/or represented both in person and electronically
at the Meeting, 8,000 shares representing 0.0002734% voted Against; 100 shares representing
0.0000034% voted Abstain; while the remainder, 2,925,938,200 shares representing 99.99972328%,
including 1 (one) Series A Dwiwarna share, voted In Favor.
In accordance with the Meeting Rules of Procedure, Shareholders who did not cast a vote (abstain) are
deemed to have cast a vote consistent with the majority vote.
Accordingly, the Meeting by majority vote through deliberation for consensus, totaling 2,925,938,300
shares representing 99.9997266% of all votes cast at the Meeting, resolved:
To approve granting authority to:
1. The Majority Series B Shareholder or its proxy to determine for the members of the Board of
   Commissioners; and
2. The Board of Commissioners, having first obtained written approval from the Majority Series B
   Shareholder or its proxy, to determine for the members of the Board of Directors,
the salary/honorarium together with facilities and allowances for Financial Year 2026 and performance-
based remuneration for Financial Year 2025, in accordance with applicable regulations.


On the Third Agenda Item of the Meeting:
Of the total shares with valid voting rights present and/or represented both in person and electronically
at the Meeting, 0 shares representing 0% voted Against; 100 shares representing 0.0000034% voted
Abstain; while the remainder, 2,925,946,200 shares representing 99.9999966%, including 1 (one) Series
A Dwiwarna share, voted In Favor.
In accordance with the Meeting Rules of Procedure, Shareholders who did not cast a vote (abstain) are
deemed to have cast a vote consistent with the majority vote.
Accordingly, the Meeting by unanimous vote through deliberation for consensus, totaling 2,925,946,300
shares representing 100% of all votes cast at the Meeting, resolved:
1.    To grant authority and power to the Company's Board of Commissioners, having first obtained
      approval from the Majority Series B Shareholder, to appoint a Public Accountant and/or Public
      Accounting Firm to audit the Company's Financial Statements for Financial Year 2026 and for other
      periods in Financial Year 2026, or to conduct specific audit of certain Financial Statements in 2026,
      as well as the Financial Statements and Implementation of the Micro and Small Business Funding
      Program (PUMK) for Financial Year 2026.
2.    To grant authority and power to the Board of Commissioners, having first obtained approval from
      the Majority Series B Shareholder, to determine the appointment of a Public Accountant and/or
      Public Accounting Firm to audit the Company's Financial Statements for other periods in Financial
      Year 2026 for the purposes and interests of the Company.

3.   To grant authority and power to the Company's Board of Commissioners, having first obtained
     written approval from the Majority Series B Shareholder, to determine the audit fee and other
     terms for the said Public Accountant and/or Public Accounting Firm, and to appoint a replacement
     Public Accountant and/or Public Accounting Firm should the original Public Accountant and/or
     Public Accounting Firm, for any reason, be unable to complete the audit of the Company's Financial
     Statements and the PUMK Program Financial Statements for Financial Year 2026, including
     determining the audit fee and other terms for the replacement.


On the Fourth Agenda Item of the Meeting:
Of the total shares with valid voting rights present and/or represented both in person and electronically
at the Meeting, 0 shares representing 0% voted Against; 100 shares representing 0.0000034% voted
Abstain; while the remainder, 2,925,946,200 shares representing 99.9999966%, including 1 (one) Series
A Dwiwarna share, voted In Favor.
In accordance with the Meeting Rules of Procedure, Shareholders who did not cast a vote (abstain) are
deemed to have cast a vote consistent with the majority vote.
Accordingly, the Meeting by unanimous vote through deliberation for consensus, totaling 2,925,946,300
shares representing 100% of all votes cast at the Meeting, resolved:
To approve granting authority and power to the Company's Board of Commissioners, having first
obtained written approval from the Majority Series B Shareholder or its proxy, to approve the
Company's Long-Term Plan (RJPP) for 2026–2030 and the Company's Work Plan and Budget (RKAP) for
2027 along with any amendments thereto. The approval of the RJPP for 2026–2030 and RKAP for 2027
along with any amendments shall be carried out in accordance with good corporate governance
practices and applicable regulations, with due regard to the principles of fairness and information
transparency, and shall have been coordinated with the Series A Dwiwarna Shareholder or its proxy for
alignment with Government policies.
On the Fifth Agenda Item of the Meeting:
Of the total shares with valid voting rights present and/or represented both in person and electronically
at the Meeting, 0 shares representing 0% voted Against; 100 shares representing 0.0000034% voted
Abstain; while the remainder, 2,925,946,200 shares representing 99.9999966%, including 1 (one) Series
A Dwiwarna share, voted In Favor.
In accordance with the Meeting Rules of Procedure, Shareholders who did not cast a vote (abstain) are
deemed to have cast a vote consistent with the majority vote.
Accordingly, the Meeting by unanimous vote through deliberation for consensus, totaling 2,925,946,300
shares representing 100% of all votes cast at the Meeting, resolved:
There are no changes to the composition of the Company's Management.


                                        Jakarta, June 29, 2026
                                        The Board of Directors